Coherus Oncology, Inc. (FRA:8C5)
Germany · Delayed Price · Currency is EUR 1.901
+0.075 (4.11%)
At close: Jan 30, 2026
Coherus Oncology Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 154.97 | 28.51 | -237.89 | -291.75 | -287.1 | 132.24 |
Depreciation & Amortization | 4.06 | 5.28 | 3.79 | 3.7 | 3.45 | 2.89 |
Other Amortization | 4.16 | 4.16 | 2.41 | 6.43 | 4.26 | 3.48 |
Loss (Gain) From Sale of Assets | -176.59 | -176.59 | - | - | - | - |
Asset Writedown & Restructuring Costs | 2.15 | 10.57 | - | - | 3.21 | - |
Loss (Gain) From Sale of Investments | - | - | - | - | 1.1 | - |
Stock-Based Compensation | 20.57 | 27.8 | 43.11 | 50.74 | 51.36 | 38.16 |
Other Operating Activities | 30.18 | 23.94 | 50.53 | 69.02 | 143.93 | 12.02 |
Change in Accounts Receivable | 158.22 | 149.35 | -150.68 | 13.05 | 34.06 | -15.22 |
Change in Inventory | -22.45 | -31.95 | -46.73 | -47.35 | -6.25 | -38.36 |
Change in Accounts Payable | -8.13 | -3.94 | 23.76 | -4.55 | 0.87 | -9.82 |
Change in Other Net Operating Assets | -95.29 | -57.57 | 136.83 | -40.41 | 13.68 | 28.75 |
Operating Cash Flow | -90.19 | -20.44 | -174.88 | -241.12 | -37.43 | 154.15 |
Operating Cash Flow Growth | - | - | - | - | - | 443.63% |
Capital Expenditures | - | - | - | - | -1.29 | -7.23 |
Sale of Property, Plant & Equipment | - | - | - | - | - | 0.18 |
Cash Acquisitions | - | - | 7 | - | - | - |
Divestitures | 227.82 | 227.82 | - | - | - | - |
Sale (Purchase) of Intangibles | -12.5 | -12.5 | - | -35 | - | -7.5 |
Investment in Securities | -87.93 | 14.89 | 138.14 | -127.38 | -1.12 | 0.16 |
Other Investing Activities | 249.99 | 0.11 | -0.49 | -4.47 | -136 | - |
Investing Cash Flow | 377.38 | 230.32 | 144.64 | -166.85 | -138.41 | -14.4 |
Long-Term Debt Issued | - | 36.98 | - | 240.68 | - | 222.16 |
Long-Term Debt Repaid | - | -260.39 | - | -190.75 | - | - |
Net Debt Issued (Repaid) | -233.19 | -223.41 | - | 49.93 | - | 222.16 |
Issuance of Common Stock | 0.72 | 2.67 | 74.22 | 9.37 | 54.3 | 21.23 |
Repurchase of Common Stock | -0.29 | -2.48 | -3.59 | -3.74 | -1.75 | -0.88 |
Other Financing Activities | -48.8 | 36.24 | -1.03 | -1.23 | -0.67 | -18.56 |
Financing Cash Flow | -281.56 | -186.97 | 69.6 | 54.33 | 51.88 | 223.95 |
Net Cash Flow | 5.64 | 22.91 | 39.36 | -353.65 | -123.96 | 363.69 |
Free Cash Flow | -90.19 | -20.44 | -174.88 | -241.12 | -38.72 | 146.91 |
Free Cash Flow Growth | - | - | - | - | - | 453.70% |
Free Cash Flow Margin | -32.47% | -7.66% | -67.98% | -114.25% | -11.86% | 30.88% |
Free Cash Flow Per Share | -0.78 | -0.18 | -1.86 | -3.11 | -0.51 | 1.76 |
Cash Interest Paid | 25.38 | 25.38 | 37.86 | 34.88 | 18.68 | 16.96 |
Cash Income Tax Paid | - | -0.11 | -0.12 | 0.04 | 1.22 | 3.95 |
Levered Free Cash Flow | 29.65 | 41.59 | -69.86 | -186.86 | -60.97 | 83.04 |
Unlevered Free Cash Flow | 41.17 | 54.4 | -46.93 | -173 | -50.88 | 92.78 |
Change in Working Capital | 32.36 | 55.89 | -36.83 | -79.26 | 42.36 | -34.65 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.